Peptide API Supply Chain Qualification: US Buyer Checklist

Approve a peptide API supply chain only after six gates pass: regulatory fit, chain of custody, critical materials, site quality and testing, transport, and continuity. Each gate needs named sites, batch-linked records, an accountable owner, and a written approval decision.

An API is the active pharmaceutical ingredient in a drug product. FDA treats APIs as drug components for import purposes, so the supply-chain record must match the actual product, manufacturer, importer, and intended use. FDA’s import guidance explains the applicable checks at entry.

Use This Peptide API Qualification Record

Start every new supplier review with one record for one peptide, one intended use, and one proposed supply route. Copy the fields below into your quality-management system before requesting a quote.

Our operational rule: an unresolved Critical item puts the supply chain on hold. A Conditional decision needs a named owner, corrective action, and due date. QA owns the final approval.

1. Regulatory Fit

   • Evidence requested: intended use, dosage form, destination, importer of record, receiving site, and applicable filing or investigational status.
   • Owner: Regulatory and QA.
   • Risk: Critical.
   • Decision: ☐ Pass ☐ Conditional ☐ Hold.

2. Named Manufacturer and Chain of Custody

   • Evidence requested: legal manufacturer and addresses for synthesis, purification, testing, packaging, storage, export, transport, and US receipt.
   • Owner: Procurement and QA.
   • Risk: Critical.
   • Decision: ☐ Pass ☐ Conditional ☐ Hold.

3. Site Quality Evidence

   • Evidence requested: GMP evidence for each manufacturing and testing site, site scope, quality-system summary, audit evidence, and compliance-history review.
   • Owner: QA and Regulatory.
   • Risk: Critical.
   • Decision: ☐ Pass ☐ Conditional ☐ Hold.

4. Critical Starting Materials and Intermediates

   • Evidence requested: critical amino acids, protected amino acids, coupling reagents, resins, purification media, intermediates, actual manufacturers, approved sources, and source-change controls.
   • Owner: QA and CMC.
   • Risk: High.
   • Decision: ☐ Pass ☐ Conditional ☐ Hold.

5. Process and Outsourced Operations

   • Evidence requested: process-flow map covering synthesis, cleavage, purification, salt or counter-ion step, lyophilization, packaging, and subcontracted work.
   • Owner: CMC and QA.
   • Risk: High.
   • Decision: ☐ Pass ☐ Conditional ☐ Hold.

6. Batch Traceability and Release

   • Evidence requested: representative batch-record index, lot genealogy, signed COA, specification, release authorization, retain-sample policy, and recall procedure.
   • Owner: QA.
   • Risk: Critical.
   • Decision: ☐ Pass ☐ Conditional ☐ Hold.

7. Specifications and Analytical Evidence

   • Evidence requested: test methods and acceptance criteria for identity, assay or content, related substances, residual solvents, water, elemental impurities, microbiological quality, and endotoxin where applicable.
   • Owner: QC and CMC.
   • Risk: High.
   • Decision: ☐ Pass ☐ Conditional ☐ Hold.

8. Analytical-Method Transfer

   • Evidence requested: method SOPs, validation summaries, reference-standard plan, system-suitability criteria, chromatograms, and transfer or comparative-testing protocol.
   • Owner: QC and CMC.
   • Risk: High.
   • Decision: ☐ Pass ☐ Conditional ☐ Hold.

9. Quality Agreement

   • Evidence requested: responsibilities for release, deviations, out-of-specification results, complaints, recalls, audits, data access, and change notifications.
   • Owner: QA and Legal.
   • Risk: Critical.
   • Decision: ☐ Pass ☐ Conditional ☐ Hold.

10. Packaging and Transport

• Evidence requested: pack configuration, labeled storage conditions, carrier, shipping lane, temperature logger, excursion process, customs-hold plan, and receiving inspection.
• Owner: Supply Chain and QA.
• Risk: High.
• Decision: ☐ Pass ☐ Conditional ☐ Hold.

11. First-Lot Release

• Evidence requested: sample plan, incoming-test plan, shipment-record review, quarantine status, deviation review, and QA release signature.
• Owner: QC and QA.
• Risk: High.
• Decision: ☐ Pass ☐ Conditional ☐ Hold.

12. Continuity and Requalification

• Evidence requested: capacity allocation, lead-time commitment, inventory policy, shortage contacts, alternate supplier status, and change-triggered requalification plan.
• Owner: Procurement and QA.
• Risk: High.
• Decision: ☐ Pass ☐ Conditional ☐ Hold.

What Must a Peptide API Supply Chain Prove Before Approval?

The supply chain must prove where the API was made, tested, released, stored, and handed over. A distributor name alone is not a manufacturing history.

Begin with the intended US use. Record whether the material supports a clinical, commercial, development, or other regulated activity. FDA reviewers compare entry information with their systems, including the declared manufacturer, importer, product description, intended-use code, and applicable affirmations. FDA import review can delay or detain an entry when records do not match.

Then map every handoff in sequence:

1. Critical raw-material manufacturer.
2. Peptide synthesis site.
3. Purification and isolation site.
4. Testing laboratory.
5. Packaging and storage site.
6. Exporter and carrier.
7. US importer and receiving warehouse.
8. Buyer’s sampling, quarantine, and release point.

Use the exact legal entity and street address at each point. Reconcile those details against the quotation, quality agreement, COA, container label, commercial invoice, and import paperwork.

FDA registration is useful for checking an establishment’s current status. It is not product approval or FDA verification of the information a firm submitted. FDA’s registration system states that distinction clearly.

Which Documents Should You Request from a Peptide API Supplier?

Ask for documents in four groups, not one unstructured data room. The request sequence helps QA identify gaps before the first batch arrives.

Before technical selection: product specification, sample COA, manufacturing-site list, process-flow map, storage conditions, packaging description, and regulatory-support summary.

Before supplier approval: GMP evidence for named sites, quality-system summary, audit package, quality agreement, critical-material control summary, change-control procedure, and continuity plan.

Before first-lot release: signed batch COA, release authorization, lot genealogy, shipping records, temperature data, commercial documents, and receiving inspection.

During the relationship: deviations, complaints, OOS investigations, annual quality review, site changes, method changes, critical-material changes, and delivery performance.

A Drug Master File can support a US regulatory submission, but it is confidential. The holder authorizes FDA to refer to relevant information through a letter of authorization. FDA’s DMF guidance lists the required elements of that letter.

How Do You Assess Starting-Material and Intermediate Risk?

Assess every critical material by its actual manufacturer, not only the company that invoices the API supplier. ICH Q7 expects API manufacturers to evaluate critical-material suppliers, buy against agreed specifications, and know the name and address of the actual manufacturer when the supplier is not that manufacturer. ICH Q7 materials controls provide the framework.

Build a critical-material register with these fields:

• Material name and process role.
• Actual manufacturer and manufacturing location.
• Approved supplier and distributor.
• Incoming identification or test method.
• Inventory coverage and single-source exposure.
• Change-notification commitment.
• Impact on identity, impurities, yield, or delivery.

Treat a source change for a coupling reagent, resin, protected amino acid, or key intermediate as a quality event. The supplier should show how it evaluates the change, assesses product impact, and notifies the buyer.

For peptide APIs, ask how the supplier controls the stages after the defined API starting material. ICH explains that the defined starting material normally sits in the regulatory filing, while suitable controls still apply before that point. ICH Q7 Q&As explain that boundary.

How Do You Verify GMP, Testing, and Method-Transfer Readiness?

Verify the actual sites that make and test the proposed peptide. A certificate that names a company but excludes the synthesis or testing location does not complete the review.

Search the named manufacturer in FDA’s current registration database. Search FDA’s import-alert database and pharmaceutical warning letters. Save the search date, legal-name variants, and result in the supplier file.

Next, separate identity from purity. A peptide HPLC purity result measures the chromatographic method and its stated conditions. Identity needs its own evidence, often mass spectrometry, and assay or content needs its own method. Peptide HPLC purity versus content explains why those results answer different questions.

Method transfer matters when the buyer, CDMO, or contract laboratory will reproduce release testing. ICH Q2(R2) says a laboratory transfer may require partial or full revalidation and comparative analysis of representative samples. ICH Q2(R2) also supports co-validation across participating laboratories.

The quality agreement should assign testing, release, deviation, and change-control duties by party. FDA describes quality agreements as the document used to define manufacturing responsibilities under CGMP. FDA quality guidance supports that approach.

What Transport and Temperature Controls Should US Buyers Require?

Transport qualification starts with the labeled storage condition for the specific peptide. It ends with a receiving decision based on the actual shipment record.

Request the carrier name, lane, pack-out design, temperature-monitoring device, logger placement, data format, customs-hold process, and excursion escalation contact. Compare the temperature record with the approved storage and transport conditions before releasing the lot.

ICH Q7 requires appropriate storage conditions, records when conditions are critical, and transport that does not harm API quality. It also requires special conditions on the label and requires transport contractors to know and follow them. ICH Q7 distribution controls also requires batch distribution records that support recall.

Use this excursion record when a lane fails:

• API name and lot number.
• Shipper, airway bill, and route.
• Approved range and observed range.
• Start time, end time, and total duration.
• Logger file and calibration status.
• Supplier stability assessment.
• QA disposition and corrective action.

A receiving team should keep the lot in quarantine until QA closes that record.

How Do You Score Risk and Build a Backup Plan?

Score risk by evidence quality and supply impact. A clean COA cannot offset an unknown synthesis site, missing critical-material controls, or an unqualified transport lane.

Use three outcomes:

• Approve: all Critical items pass, and High items have adequate evidence.
• Conditional approval: a High item has a documented action, owner, and due date.
• Hold: any Critical item remains unresolved.

Build the backup plan during initial qualification. Name the alternate manufacturer, alternate site, alternative testing arrangement, and alternative shipping lane. Record what evidence the alternate already has and what remains before release.

ICH Q9(R1) supports risk-based oversight of suppliers and states that substantial variability can justify enhanced monitoring or a pre-qualified backup supply-chain entity. ICH Q9(R1) makes continuity a quality responsibility, not only a purchasing task.

FAQs

Can a Buyer See the Complete Drug Master File?

No, a buyer usually receives the DMF number, scope information, and a letter of authorization rather than the confidential file. The letter authorizes FDA to reference the DMF for the buyer’s submission. FDA’s DMF guidance lists the information that letter should contain.

Can a Buyer Receive Peptide API Under Quarantine?

Yes, an API can move under quarantine when the quality unit authorizes the transfer and controls and documentation are in place. The buyer should record the quarantine status, restrict use, and release the lot only after the receiving review is complete. ICH Q7 distribution rules describe that control.

What Should Trigger Supplier Requalification?

A new manufacturing or testing site, a critical-material source change, a process change, an analytical-method change, a serious deviation, or a transport failure should trigger requalification. A scheduled review should also refresh site evidence, quality performance, and continuity records.

Which Results Distinguish Peptide Identity from Purity?

Mass spectrometry commonly supports molecular identity, while HPLC commonly measures chromatographic purity under a defined method. Assay or content answers a separate quantity question. The required test package follows the product specification and intended use.

At Aarise Pharma, we supply peptide APIs including semaglutide, insulin analogs, oxytocin, and GLP-1 agonists. Our API portfolio states that each shipment includes a COA and MSDS, with CPP, DMF, and CEP documentation available on request.